Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Stereotactic Radiosurgery for Brain Tumors
share announcement

Stereotactic Radiosurgery for Brain Tumors

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Neuro-Oncology".

Deadline for manuscript submissions: closed (15 February 2025) | Viewed by 2403

Special Issue Editors

Dr. Dante Amelio

E-Mail Website
Guest Editor
Proton Therapy Center, Azienda Provinciale per i Servizi Sanitari (APSS), 38123 Trento, Italy
Interests: CNS tumors; skull base tumors; lung tumors; proton therapy; radiosurgery
Dr. Piera Navarria

E-Mail Website
Guest Editor
Radiotherapy and Radiosurgery Department, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, 20089 Milan, Italy
Interests: brain metastases; radiation therapy; radiosurgery; glioblastoma
Special Issues, Collections and Topics in MDPI journals
Dr. Giuseppe Minniti

E-Mail Website
Guest Editor
1. Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy
2. IRCCS Neuromed, Pozzilli, IS, Italy
Interests: neuro-oncology; radiotherapy in CNS cancers; radiosurgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Stereotactic radiosurgery (SRS) is the use of a high dose of radiation, stereotactically directed to an intracranial region of interest. This allows for the non-surgical treatment of intracranial pathologies, which significantly decreases the risk of morbidity.

There are currently a number of different delivery methods for SRS, including linear accelerators, Gamma or Cyber Knife units, and charged particle methods.

Radiosurgery is currently used in the treatment of brain metastases, meningiomas, vestibular schwannomas, sellar and suprasellar lesions, and arteriovenous malformations. Moreover, SRS is widely used to treat functional conditions, such as trigeminal neuralgia and intractable tremor.

Researchers and clinicians employing SRS in daily practice are invited to submit manuscripts regarding technical as well as clinical issues.

We look forward to receiving your contributions.

Dr. Dante Amelio
Dr. Piera Navarria
Dr. Giuseppe Minniti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stereotactic radiosurgery
  • gamma knife
  • cyber knife
  • particle therapy
  • brain tumors
  • skull base tumors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 1726 KiB  
Article
Impact of Multileaf Collimator Width and Normal Tissue Objective on Radiation Dose Distribution in Stereotactic Radiosurgery Using HyperArc for Single Brain Lesions
by Se An Oh, Jae Won Park, Ji Woon Yea, Jaehyeon Park and Yoon Young Jo
Curr. Oncol. 2025, 32(5), 272; https://doi.org/10.3390/curroncol32050272 - 7 May 2025
Viewed by 127
Abstract
This study retrospectively investigated the impact of stereotactic radiosurgery (SRS) normal tissue objective (NTO) and multileaf collimator (MLC) width on radiation dose distribution in patients with brain metastasis treated using HyperArc. In total, 21 patients who underwent SRS using the HyperArc of the [...] Read more.
This study retrospectively investigated the impact of stereotactic radiosurgery (SRS) normal tissue objective (NTO) and multileaf collimator (MLC) width on radiation dose distribution in patients with brain metastasis treated using HyperArc. In total, 21 patients who underwent SRS using the HyperArc of the TrueBeam linear accelerator from November 2022 to June 2024 were included. All patients received radiotherapy with HASH planned with SRS NTO and HD MLC. HyperArc(HAAH) combined with the auto NTO and HD MLC and HyperArc(HAAM) with auto NTO and millennium MLC were generated and compared. Monitor units (MU), conformity index (CI), radical dose homogeneity index (rDHI), moderate DHI (mDHI), and gradient index (GI) were evaluated as target factors, and V2(Gy), V10(Gy), V12(Gy), V18(Gy), V10(cc), and V12(cc) were evaluated as normal brain factors. Dosimetric comparisons were performed between HASH, HAAH, and HAAM and between target and normal brain tissues. Between HASH and HAAH, average MU was 7206 and 5798, respectively; the difference was significant (p < 0.001). The MU of HAAM was 5835. Among HASH, HAAH, and HAAM, CI and mDHI were not significantly different, but there were significant differences in rDHI, GI, and normal brain tissues. When treating a single lesion using HyperArc, SRS NTO influences MU and GI, and the MLC width influences rDHI and GI. In HyperArc for single metastatic brain lesions, SRS NTO and MLC width have a significant effect on the radiation dose delivered to the target and normal brain tissues. Full article
(This article belongs to the Special Issue Stereotactic Radiosurgery for Brain Tumors)
►▼ Show Figures

Figure 1

12 pages, 2765 KiB  
Article
Survival after Stereotactic Radiosurgery in the Era of Targeted Therapy: Number of Metastases No Longer Matters
by James de Boisanger, Martin Brewer, Matthew W. Fittall, Amina Tran, Karen Thomas, Sabine Dreibe, Antonia Creak, Francesca Solda, Jessica Konadu, Helen Taylor, Frank Saran, Liam Welsh and Nicola Rosenfelder
Curr. Oncol. 2024, 31(6), 2994-3005; https://doi.org/10.3390/curroncol31060228 - 28 May 2024
Cited by 1 | Viewed by 1558
Abstract
Randomised control trial data support the use of stereotactic radiosurgery (SRS) in up to 4 brain metastases (BMs), with non-randomised prospective data complementing this for up to 10 BMs. There is debate in the neuro-oncology community as to the appropriateness of SRS in [...] Read more.
Randomised control trial data support the use of stereotactic radiosurgery (SRS) in up to 4 brain metastases (BMs), with non-randomised prospective data complementing this for up to 10 BMs. There is debate in the neuro-oncology community as to the appropriateness of SRS in patients with >10 BMs. We present data from a large single-centre cohort, reporting survival in those with >10 BMs and in a >20 BMs subgroup. A total of 1181 patients receiving SRS for BMs were included. Data were collected prospectively from the time of SRS referral. Kaplan–Meier graphs and logrank tests were used to compare survival between groups. Multivariate analysis was performed using the Cox proportional hazards model to account for differences in group characteristics. Median survival with 1 BM (n = 379), 2–4 BMs (n = 438), 5–10 BMs (n = 236), and >10 BMs (n = 128) was 12.49, 10.22, 10.68, and 10.09 months, respectively. Using 2–4 BMs as the reference group, survival was not significantly different in those with >10 BMs in either our univariable (p = 0.6882) or multivariable analysis (p = 0.0564). In our subgroup analyses, median survival for those with >20 BMs was comparable to those with 2–4 BMs (10.09 vs. 10.22 months, p = 0.3558). This study contributes a large dataset to the existing literature on SRS for those with multi-metastases and supports growing evidence that those with >10 BMs should be considered for SRS. Full article
(This article belongs to the Special Issue Stereotactic Radiosurgery for Brain Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop